What drives time-to-randomization in oncology trials?
Oncology sponsors often plan enrollment with high-level epidemiology assumptions, then lose months to screen failures, dropouts, and an ill-defined biomarker strategy. This article examines analytics across the enrollment funnel to understand what drives lengthy enrollment timelines and high screen failure rates in cancer trials.
